IT
|
EN
|
FR
|
ES
|
DE
Values
Our identity
Consumer protection
Employees & partners
Mission
Environment
Code of conduct
Whistleblowing
Corporate compliance
Sustainability report
Kip for social
Corporate
Innovative PMI
Nutraceuticals
Profile and organization
Research and development
Company validations
Product validations
Patents
KIP Academy
Investors Relations
Governance
Highlights
Events and Investor day
Corporate events calendar
Financial press releases
Presentations
Shareholders’ Meetings
Financial reports
Analyst coverage
Shareholders Information
IPO
Investor relations contacts
Quality & protection
Raw materials choice
Attention to food intolerances
Study about the packs
Information in braille
Tamper Evident system
Conservation and transportation
The nutraceutic module
Products
All products
Uro-Gynecological Line
Almetax
®
Almetax Easy
®
Ivuxur
®
sachets
Ivuxur
®
tablets
Miledix
®
Xinprox
®
Orthopedic and Fisiatric Line
Dolatrox
®
Milesax
®
Xinepa
®
Xinepa Easy
®
Doltendix
®
KIP
®
Pharmacy
Kip
®
Kit
Other products
Dolatrox hcc
®
Media
News
Press review
Press kit
Contact Media Relations
Contact
For consumers
For doctors
For pharmacies and health stores
For distributors
For other subjects
For investors
Work with us
Where we are
Legal notice
Privacy
E-commerce
Language
Italiano
English
Français
Español
Deutsch
News
News from the world KOLINPHARMA
25/10/2022
- published at 16.47
KOLINPHARMA
®
signs an agreement with ASTAREAL
®
AB for distribution in the Asian market
An important three-year agreement for distribution of products in Mainland China, Hong Kong, Macao and Taiwan
05/08/2021
- published at 16.06
Kolinpharma
®
at VITAFOODS Europe 2021 in Geneva and at CPHI Worldwide 2021 in Milan
KOLINPHARMA
®
strengthens its marketing and brand awareness strategy
26/08/2020
- published at 14.14
KOLINPHARMA
®
expands its product portfolio with IVUXUR
®
TABLETS.
KOLINPHARMA
®
presents the new product IVUXUR
®
TABLETS, which is added to the other 9 patented or patent pending products
16/04/2020
- published at 14.49
KOLINPHARMA
®
:first patent for XINEPA
®
in Israel and fifth outside Italy
Xinepa
®
is a nutraceutical product already in possession of a double patent in Italy
10/03/2020
- published at 16.45
KOLINPHARMA
®
obtains the patent in the U.S. of Dolatrox
®
It is the fourth patent that is added to Ivuxur
®
and to the 2 of Xinepa
®
24/05/2019
- published at 10.54
KOLINPHARMA
®
invests in product quality and safety
Strict product controls guarantee quality and safety for the consumer.
> News archive
Media
News
Almetax Easy and tablets
Certified products
Company validations
Consumer Protection
Corporate compliance
Dolatrox
Ivuxur
Milesax
Nutraceuticals
Profile and organization
Research and development
Respect the environment
Xinepa Easy and tablets
Press review
Press Kit
Contact media relations
“Science accuracy and listen to people”
“Science accuracy and listen to people”